MCY:NZXMercury NZ Ltd. Analysis
Data as of 2026-03-15 - not real-time
$88.96
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Mercury General (MCY) posted a 32% profit surge in Q4, with revenue up 7% and a combined ratio improving to 96.3%, underscoring strong underwriting performance. The company’s free cash flow of $2.52 B and a modest payout ratio of 13% support a sustainable dividend of 1.43%. Valuation metrics are compelling: a trailing P/E of 9.1 versus an industry average of 16.4 and an estimated upside of roughly 24% suggest the stock is significantly undervalued. ROE of 24.8% and operating margin of 16.7% highlight efficient capital use, while debt-to-equity sits at a manageable 24.3%.
Technically, the share price of $88.96 sits just below the 20‑day and 50‑day SMAs (≈$89.5) and above the 200‑day SMA, indicating a neutral to slightly bearish bias. The MACD is in bearish territory and volume trends downward, adding short‑term pressure. However, a beta of 0.64 points to lower market volatility, though the 30‑day price volatility of 38% is relatively high. Overall, the fundamentals are robust and the valuation attractive, but short‑term technical signals advise caution.
Technically, the share price of $88.96 sits just below the 20‑day and 50‑day SMAs (≈$89.5) and above the 200‑day SMA, indicating a neutral to slightly bearish bias. The MACD is in bearish territory and volume trends downward, adding short‑term pressure. However, a beta of 0.64 points to lower market volatility, though the 30‑day price volatility of 38% is relatively high. Overall, the fundamentals are robust and the valuation attractive, but short‑term technical signals advise caution.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bearish MACD histogram and decreasing volume
- Price hovering just below short‑term moving averages
- Recent earnings surprise may already be priced in
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Strong earnings growth and 14% revenue expansion YoY
- Undervalued relative to peers with ~24% upside potential
- Robust cash generation supporting dividend and debt repayment
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- High ROE and stable combined ratio indicating durable profitability
- Low payout ratio offering dividend sustainability and growth
- Favorable valuation metrics and solid balance sheet for long‑run upside
Key Metrics & Analysis
Financial Health
Revenue Growth14.10%
Profit Margin9.03%
P/E Ratio9.1
ROE24.80%
ROA4.82%
Debt/Equity24.32
P/B Ratio2.0
Op. Cash Flow$1.1B
Free Cash Flow$2.5B
Industry P/E16.4
Technical Analysis
TrendNeutral
RSI47.6
Support$82.42
Resistance$100.06
MA 20$89.51
MA 50$89.84
MA 200$80.81
MACDBearish
VolumeDecreasing
Fear & Greed Index72.88
Valuation
Fair Value$1,135.00
Target Price$110.00
Upside/Downside23.65%
GradeUndervalued
TypeBlend
Dividend Yield1.43%
Risk Assessment
Beta0.64
Volatility38.52%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.